STOCK TITAN

Amneal to Report Third Quarter 2023 Results on November 7, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Amneal Pharmaceuticals to release Q3 2023 financial results
Positive
  • Amneal Pharmaceuticals, Inc. will release its third quarter 2023 financial results on November 7, 2023, prior to market open.
Negative
  • None.

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2023 financial results on Tuesday, November 7, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time.

The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com.

Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and unique PIN which will allow them to access the call.

To access the call through a conference line, dial 1 (833) 470-1428 (in the U.S.) or for a list of toll-free international numbers, visit this link. The access code for the call is 605508.

A replay of the conference call will be posted shortly after the call and will be available for seven days.

About Amneal
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully integrated global pharmaceuticals company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of approximately 270 pharmaceutical products, primarily within the United States. In its Generics segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com.

Investor Contact

Anthony DiMeo

Head of Investor Relations

anthony.dimeo@amneal.com

Source: Amneal Pharmaceuticals, Inc.

FAQ

When will Amneal Pharmaceuticals release its Q3 2023 financial results?

Amneal Pharmaceuticals will release its Q3 2023 financial results on November 7, 2023, prior to market open.

Where can I access the financial results and live webcast?

The financial results and live webcast will be accessible through the Investor Relations section of Amneal Pharmaceuticals' website at https://investors.amneal.com.

How can I register for the conference call?

You can register for the conference call by clicking the provided link in the PR.

What is the access code for the call?

The access code for the call is 605508.

Will there be a replay of the conference call?

Yes, a replay of the conference call will be posted shortly after the call and will be available for seven days.

Amneal Pharmaceuticals, Inc.

NASDAQ:AMRX

AMRX Rankings

AMRX Latest News

AMRX Stock Data

2.01B
123.43M
59.78%
29.02%
0.78%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Bridgewater

About AMRX

an american pharmaceutical company, amneal develops and produces affordable medicines. the company was built upon a family tradition of quality and integrity. everything amneal does, across the full spectrum of its business, is in service to these guiding principles. amneal is committed to constantly elevating and refining the value it delivers to its customers and patients around the globe.